- Home
- ROMA vs LGVN Comparison
ROMA vs LGVN Comparison
Compare ROMA & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROMA
- LGVN
- Stock Information
- Founded
- ROMA 2018
- LGVN 2014
- Country
- ROMA Hong Kong
- LGVN United States
- Employees
- ROMA N/A
- LGVN N/A
- Industry
- ROMA Savings Institutions
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- ROMA Finance
- LGVN Health Care
- Exchange
- ROMA Nasdaq
- LGVN Nasdaq
- Market Cap
- ROMA 150.7M
- LGVN 16.4M
- IPO Year
- ROMA 2024
- LGVN 2021
- Fundamental
- Price
- ROMA $3.30
- LGVN $0.75
- Analyst Decision
- ROMA
- LGVN Strong Buy
- Analyst Count
- ROMA 0
- LGVN 2
- Target Price
- ROMA N/A
- LGVN $6.50
- AVG Volume (30 Days)
- ROMA 38.8K
- LGVN 481.9K
- Earning Date
- ROMA 09-25-2025
- LGVN 11-11-2025
- Dividend Yield
- ROMA N/A
- LGVN N/A
- EPS Growth
- ROMA N/A
- LGVN N/A
- EPS
- ROMA N/A
- LGVN N/A
- Revenue
- ROMA $1,568,345.00
- LGVN $2,073,000.00
- Revenue This Year
- ROMA N/A
- LGVN N/A
- Revenue Next Year
- ROMA N/A
- LGVN N/A
- P/E Ratio
- ROMA N/A
- LGVN N/A
- Revenue Growth
- ROMA 23.21
- LGVN 68.67
- 52 Week Low
- ROMA $0.54
- LGVN $0.63
- 52 Week High
- ROMA $4.66
- LGVN $2.48
- Technical
- Relative Strength Index (RSI)
- ROMA 61.52
- LGVN 35.36
- Support Level
- ROMA $2.28
- LGVN $0.78
- Resistance Level
- ROMA $3.40
- LGVN $0.85
- Average True Range (ATR)
- ROMA 0.34
- LGVN 0.05
- MACD
- ROMA 0.13
- LGVN 0.02
- Stochastic Oscillator
- ROMA 95.70
- LGVN 20.82
About ROMA Roma Green Finance Limited
Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.